The Effectiveness of Zoster Vaccine in Patients Subsequently Treated With Tofacitinib
Bibliographic record
Abstract
Introduction: Tofacitinib is an oral, small molecule JAK inhibitor approved for the treatment of rheumatoid arthritis (RA) currently being investigated for several immune-mediated inflammatory diseases incl. ulcerative colitis. Patients (pts) with these conditions can be at increased risk for herpes zoster (HZ). Live zoster vaccine (LZV) has shown 70% and 51% efficacy in immunocompetent adults aged 50-59 and ≥60 years, respectively.1 LZV is recommended to be used in pts over 50 years old prior to starting immunosuppression with biologic disease-modifying antirheumatic drugs.2,3 We recently documented this vaccine to provide adequate immune responses in RA pts receiving methotrexate prior to starting tofacitinib.4 Here, we report long-term follow-up data of this cohort evaluating the effectiveness of LZV. Methods: The initial study involved 112 RA pts given LZV and randomized 2-3 weeks (wks) later to tofacitinib 5 mg twice daily (BID) or placebo for 12 wks (NCT02147587). At 14 wks, pts were offered inclusion in the long-term extension study ORAL Sequel (NCT00413699) at doses of either 5 or 10 mg BID. From this cohort, we calculated incidence of HZ after tofacitinib start, up to 27 months after. Among HZ cases, we analyzed varicella zoster virus (VZV)-specific immunity with average immunity after LZV. Results: Of 112 randomized pts (placebo, n=57; 5 mg BID, n=55), 100 continued to receive tofacitinib in ORAL Sequel. Five cases (not adjudicated) of HZ occurred at 202, 267, 702, 699, 446 days after initiation of tofacitinib in Cases 1-5, respectively. Cases #1-4 were monodermatomal; #5 involved 5 dermatomes; all resolved with treatment. Cases #1, #4, and #5 had undetectable VZV cell-mediated immunity (measured by ELISPOT) at baseline (BL) and Wk 6 post-vaccination, indicating a lack of VZV-specific immunity. Cases #2 and #3 responded adequately to vaccination by both immunoglobulin G (IgG) and ELISPOT measures, but had lower than average VZV IgG levels at BL and Wk 6. Conclusion: LZV prior to treatment with tofacitinib is effective at boosting IgG levels and cell-mediated immunity towards VZV. Of the 5 pts who developed HZ, 3 did not have any cell-mediated response and 2 had a low humoral response. Funded by Pfizer Inc.Table: Table. VZV ELISPOT and IgG levels
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.002 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.002 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".